Castle Biosciences 調升 2026 年營收指引至 3.65 億至 3.75 億美元，TissueCypher 銷量成長趨勢達 50%-52% ($CSTL)
· seekingalpha.com
Castle Biosciences ($CSTL) 2026 年第二季法說會重點摘要：營收成長 20%、調升財務指引、TissueCypher 需求激增，但需注意利潤率與平均銷售單價 (ASP) 風險。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...